Insulin degludec/insulin aspart

Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.^[6][7][8][9] It contains insulin degludec and insulin aspart.^[6] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.^[6]

Insulin degludec/insulin aspart

Combination of
Insulin degludec	Long-acting human insulin analog
Insulin aspart	Fast-acting human insulin analog
Clinical data
Trade names	Ryzodeg
AHFS/Drugs.com	Professional Drug Facts
Pregnancy category	AU: B3[1][2]
Routes of administration	Subcutaneous injection
ATC code	A10AD06 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[2][3][4][5] EU: Rx-only[6]
Identifiers
CAS Number	1392491-77-8
KEGG	D10570

The most frequently reported side effect is hypoglycemia (low blood glucose levels).^[6]

It was approved for medical use in the European Union in January 2013,^[6] and in Australia in November 2017.^[2]

Medical uses

Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.^[6]

Insulin degludec and insulin aspart are slightly different from human insulin.^[6] The differences mean that insulin degludec is absorbed more slowly by the body.^[6] This means it has a long duration of action.^[6] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.^[6]